

Thw

DOCKET NO. CEN5021NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Marc Mercken, et al.

Serial No.: 10/810,881

Art Unit: 1645

Filed : March 26, 2004

Examiner:

For : ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, METHODS AND USES

CERTIFICATE OF MAILING OR TRANSMISSION	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on:	
November 3, 2005	/Guy Kevin Townsend/
Date	Signature
Guy Kevin Townsend	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national

application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Statement in Accordance with §1.97(e) (attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

☐ Statement in Accordance with §1.97(e) (attached); or
☐ Please charge Deposit Account No. 10-
0750/ / the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☒ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2).

☒ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☒ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.

☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.


Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN5021NP/GKT. This form is submitted in triplicate.

Respectfully submitted,

/Guy Kevin Townsend/

Guy Kevin Townsend
Registration No. 34,033
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
732.524.2517
Dated: November 3, 2005



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1993, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Application Number

Filing Date

March 26, 2004

First Named Inventor

Marc Mercken, et al.

Group Art Unit

Examiner Name

Attorney Docket Number

CEN5021NP

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code* (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ²
		Office ³	Number ⁴	Kind Code ⁵				
		WO	02/46237	A	PCT	06/13/2002		
		WO	02/088307	A	PCT	11/07/2002		
		EP	1172378	A	EP	01/16/2002		
		WO	02088306	A	WO	11/07/2002		
		WO	03016467	A	WO	02/27/2003		
		WO	2004029630	A	WO	04/08/2004		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		J. DAVIES, et al., "Affinity Improvement of Single Antibody VH Domains: Residues in All Three Hypervariable Regions Affect Antigen Binding," IMMUNOTECHNOLOGY, Vol. 2, 1998, pgs 169-179.	
		L. HOLT, et al., "Domain Antibodies: Proteins for Therapy," TRENDS IN BIOTECHNOLOGY, Vol. 21, no. 11, November 2003 (2003-11), pgs 484-490.	
		Q. FANG, et al., "VH and VL Gene Usage by Anti-Beta-Amyloid Autoantibodies in Alzheimer's Disease: Detection of Highly Mutated V Regions in Both Heavy and Light Chains," CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, Vol. 75, no. 2, May 1995 (1995-05), pgs 159-167.	
		J. CAI, et al., "Screening and Characterization of Human Single-Chain Fv Antibody Against Beta-Amyloid Peptide 40," NEUROREPORT, Vol. 14, No. 2, 10 February 2003 (2003-02-10), pgs 265-268.	
		F. GASKIN, et al., "Human Antibodies Reactive with Beta-Amyloid Protein in Alzheimer's Disease," JOURNAL OF EXPERIMENTAL MEDICINE, Vol. 177, No. 4, April 1993 (1993-04), pgs 1181-1186.	
		F. KAMETANI, et al., "A Monoclonal Antibody Hy20-54-16-3L to 1ambda Light Chain of Human Immunoglobulin Reacts with Amyloid in Alzheimer's Disease Brain," NEUROSCIENCE LETTERS, Vol. 117, No. 3/4, 1990, pgs 62-67.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

